|
1
|
Frebourg T, Bajalica Lagercrantz S,
Oliveira C, Magenheim R and Evans DG: European Reference Network
GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related
cancer syndromes. Eur J Hum Genet. 28:1379–1386. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Miranda Alcalde B, Villa Alcázar M,
Martínez Romera I and López Ibor B: The importance of Li-Fraumeni
syndrome, a hereditary cancer predisposition disorder. Arch Argent
Pediatr. 119:e11–e17. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fortuno C, Lee K, Olivier M, Pesaran T,
Mai PL, de Andrade KC, Attardi LD, Crowley S, Evans DG, Feng BJ, et
al: Specifications of the ACMG/AMP variant interpretation
guidelines for germline TP53 variants. Hum Mutat. 42:223–236.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wade KS, Estes JM and Kline RC: Genetics
and the Gynecologic Patient. Ochsner J. 20:446–451. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ueki A and Hirasawa A: Molecular features
and clinical management of hereditary gynecological cancers. Int J
Mol Sci. 21(9504)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mai PL, Best AF, Peters JA, DeCastro RM,
Khincha PP, Loud JT, Bremer RC, Rosenberg PS and Savage SA: Risks
of first and subsequent cancers among TP53 mutation carriers in the
National Cancer Institute Li-Fraumeni syndrome cohort. Cancer.
122:3673–3681. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Monti P, Menichini P, Speciale A, Cutrona
G, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, et al:
Heterogeneity of TP53 Mutations and P53 Protein Residual
Function in Cancer: Does It Matter? Front Oncol.
10(593383)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zawacka-Pankau JE: The undervalued avenue
to reinstate tumor suppressor functionality of the p53 protein
family for improved cancer therapy-drug repurposing. Cancers
(Basel). 12(2717)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Levine AJ: p53: 800 million years of
evolution and 40 years of discovery. Nat Rev Cancer. 20:471–480.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fortuno C, Pesaran T, Mester J, Dolinsky
J, Yussuf A, McGoldrick K, James PA and Spurdle AB:
Genotype-phenotype correlations among TP53 carriers: Literature
review and analysis of probands undergoing multi-gene panel testing
and single-gene testing. Cancer Genet. 248-249:11–17.
2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Volc SM, Ramos CRN, Galvão HCR, Felicio
PS, Coelho AS, Berardineli GN, Campacci N, Sabato CDS,
Abrahao-Machado LF, Santana IVV, et al: The Brazilian TP53 mutation
(R337H) and sarcomas. PLoS One. 15(e0227260)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Amadou A, Achatz MIW and Hainaut P:
Revisiting tumor patterns and penetrance in germline TP53 mutation
carriers: Temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol.
30:23–29. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Consul N, Amini B, Ibarra-Rovira JJ, Blair
KJ, Moseley TW, Taher A, Shah KB and Elsayes KM: Li-Fraumeni
syndrome and Whole-body MRI screening: Screening guidelines,
imaging features, and impact on patient management. AJR Am J
Roentgenol. 216:252–263. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Grasparil AD II, Gottumukkala RV, Greer MC
and Gee MS: Whole-body MRI surveillance of cancer predisposition
syndromes: Current best practice guidelines for use, performance,
and interpretation. AJR Am J Roentgenol. 215:1002–1011.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Iwasaki T, Mizumoto M, Numajiri H, Oshiro
Y, Suzuki R, Moritani K, Eguchi M, Ishii E and Sakurai H:
Re-irradiation using proton therapy for radiation-induced secondary
cancer with Li-Fraumeni syndrome: A case report and review of
literature. J Cancer Res Ther. 16:1524–1527. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Eulo V, Lesmana H, Doyle LA, Nichols KE
and Hirbe AC: Secondary sarcomas: Biology, presentation, and
clinical care. Am Soc Clin Oncol Educ Book. 40:1–12.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pang LK, Pena M, Zhao R and Lee DF:
Modeling of osteosarcoma with induced pluripotent stem cells. Stem
Cell Res. 49(102006)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Czarnecka AM, Synoradzki K, Firlej W,
Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P:
Molecular biology of osteosarcoma. Cancers (Basel).
12(2130)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schneider KW, Cost NG, Schultz KAP,
Svihovec S and Suttman A: Germline predisposition to genitourinary
rhabdomyosarcoma. Transl Androl Urol. 9:2430–2440. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sandru F, Carsote M, Valea A, Albu SE,
Petca RC and Dumitrascu MC: Somatostatinoma: Beyond
neurofibromatosis type 1 (Review). Exp Ther Med. 20:3383–3388.
2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Evans DG, Woodward ER,
Bajalica-Lagercrantz S, Oliveira C and Frebourg T: Germline TP53
testing in breast cancers: Why, when and how? Cancers (Basel).
12(3762)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Le AN, Harton J, Desai H, Powers J, Zelley
K, Bradbury AR, Nathanson KL, Shah PD, Doucette A, Freedman GM, et
al: Frequency of radiation-induced malignancies post-adjuvant
radiotherapy for breast cancer in patients with Li-Fraumeni
syndrome. Breast Cancer Res Treat. 181:181–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Piombino C, Cortesi L, Lambertini M, Punie
K, Grandi G and Toss A: Secondary prevention in hereditary breast
and/or ovarian cancer syndromes other than BRCA. J Oncol.
2020(6384190)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fortuno C, James PA and Spurdle AB:
Current review of TP53 pathogenic germline variants in breast
cancer patients outside Li-Fraumeni syndrome. Hum Mutat.
39:1764–1773. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Petry V, Bonadio RC, Cagnacci AQC, Senna
LAL, Campos RDNG, Cotti GC, Hoff PM, Fragoso MCBV and Estevez-Diz
MDP: Radiotherapy-induced malignancies in breast cancer patients
with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam
Cancer. 19:47–53. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Orr BA, Clay MR, Pinto EM and Kesserwan C:
An update on the central nervous system manifestations of
Li-Fraumeni syndrome. Acta Neuropathol. 139:669–687.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Xiong Y, Zhang Y, Xiong S and
Williams-Villalobo AE: A Glance of p53 functions in brain
development, neural stem cells, and brain cancer. Biology (Basel).
9(285)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Valdez JM, Nichols KE and Kesserwan C:
Li-Fraumeni syndrome: A paradigm for the understanding of
hereditary cancer predisposition. Br J Haematol. 176:539–552.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Swaminathan M, Bannon SA, Routbort M,
Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F,
Patel KP, Champlin R, et al: Hematologic malignancies and
Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud.
5(a003210)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jouinot A and Bertherat J: Diseases
predisposing to adrenocortical malignancy (Li-Fraumeni syndrome,
Beckwith-Wiedemann syndrome, and carney Complex). Exp Suppl.
111:149–169. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Petr EJ and Else T: Adrenocortical
carcinoma (ACC): When and why should we consider germline testing?
Presse Med. 47:e119–e125. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Carsote M, Ghemigian A, Terzea D,
Gheorghisan-Galateanu AA and Valea A: Cystic adrenal lesions: Focus
on pediatric population (a review). Clujul Med. 90:5–12.
2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kamihara J, Rana HQ and Garber JE:
Germline TP53 mutations and the changing landscape of Li-Fraumeni
syndrome. Hum Mutat. 35:654–662. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Baek YS, Seo JY, Song JY, Lee SY, Kim A
and Jeon J: Li-Fraumeni syndrome presenting as cutaneous melanoma
in a child: Case report and review of literature. J Eur Acad
Dermatol Venereol. 33:e174–e175. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Akay BN, Okcu Heper A, Topcu V and Farabi
B: A rare case of multiple cutaneous melanomas in Li-Fraumeni
syndrome: A coincidental association or a component of the
syndrome? Australas J Dermatol. 60:e214–e216. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Curiel-Lewandrowski C, Speetzen LS,
Cranmer L, Warneke JA and Loescher LJ: Multiple primary cutaneous
melanomas in Li-Fraumeni syndrome. Arch Dermatol. 147:248–250.
2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kollipara R, Cooley LD, Horii KA,
Hetherington ML, Leboit PE, Singh V and Zwick DL: Spitzoid melanoma
in a child with Li-Fraumeni syndrome. Pediatr Dev Pathol. 17:64–69.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jacquemus J, Perron E, Pissaloux D,
Alberti L and de la Fouchardière A: Atypical cutaneous melanocytic
tumours arising in two patients with Li-Fraumeni syndrome.
Pathology. 49:801–805. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Klein JD and Kupferman ME: Li-Fraumeni
syndrome presenting as mucosal melanoma: Case report and treatment
considerations. Head Neck. 39:E20–E22. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hajkova N, Hojny J, Nemejcova K, Dundr P,
Ulrych J, Jirsova K, Glezgova J and Ticha I: Germline mutation in
the TP53 gene in uveal melanoma. Sci Rep. 8(7618)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Calvete O, Garcia-Pavia P, Domínguez F,
Bougeard G, Kunze K, Braeuninger A, Teule A, Lasa A, Ramón Y, Cajal
T, et al: The wide spectrum of POT1 gene variants correlates with
multiple cancer types. Eur J Hum Genet. 25:1278–1281.
2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Giavedoni P, Ririe M, Carrera C, Puig S
and Malvehy J: Familial melanoma associated with Li-Fraumeni
syndrome and atypical mole syndrome: Total-body digital
photography, dermoscopy and confocal microscopy. Acta Derm
Venereol. 97:720–723. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sabater-Marco V, Ferrando-Roca F,
Morera-Faet A, García-García JA, Bosch SB and López-Guerrero JA:
Primary cutaneous leiomyosarcoma arising in a patient With
Li-Fraumeni Syndrome: A neoplasm with unusual histopathologic
features and loss of heterozygosity at TP53 Gene. Am J
Dermatopathol. 40:225–227. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nieuwenburg SA, Adan F, Ruijs MWG, Sonke
GS, van Leerdam ME and Crijns MB: Cumulative risk of skin cancer in
patients with Li-Fraumeni syndrome. Fam Cancer. 19:347–351.
2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Park KJ, Choi HJ, Suh SP, Ki CS and Kim
JW: Germline TP53 mutation and clinical characteristics of Korean
patients with Li-Fraumeni syndrome. Ann Lab Med. 36:463–468.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Chan AK, Han SJ, Choy W, Beleford D, Aghi
MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, et al:
Familial melanoma-astrocytoma syndrome: Synchronous diffuse
astrocytoma and pleomorphic xanthoastrocytoma in a patient with
germline CDKN2A/B deletion and a significant family history. Clin
Neuropathol. 36:213–221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hsieh CC and Shen CH: The potential of
targeting P53 and HSP90 overcoming acquired MAPKi-resistant
melanoma. Curr Treat Options Oncol. 20(22)2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pandey R, Johnson N, Cooke L, Johnson B,
Chen Y, Pandey M, Chandler J and Mahadevan D: TP53 Mutations as a
driver of metastasis signaling in advanced cancer patients. Cancers
(Basel). 13(597)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Alos L, Fuster C, Castillo P, Jares P,
Garcia-Herrera A, Marginet M, Agreda F, Arance A, Gonzalvo E,
Garcia M, et al: TP53 mutation and tumoral PD-L1 expression are
associated with depth of invasion in desmoplastic melanomas. Ann
Transl Med. 8(1218)2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Loureiro JB, Abrantes M, Oliveira PA and
Saraiva L: P53 in skin cancer: From a master player to a privileged
target for prevention and therapy. Biochim Biophys Acta Rev Cancer.
1874(188438)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Guo L, Kang JS, Kang NJ and Choi YW:
S-petasin induces apoptosis and inhibits cell migration through
activation of p53 pathway signaling in melanoma B16F10 cells and
A375 cells. Arch Biochem Biophys. 692(108519)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Carsote M, Valea A, Dumitru N, Terzea D,
Petrova E, Albu S, Buruiana A and Ghemigian A: Metastases in daily
endocrine practice. Arch Balkan Med Union. 51:478–482. 2016.
|
|
53
|
Baloescu R, Carsote M, Albu SE and Valea
A: Multiple surgeries and long-term endocrine follow-up in a MEN2A
syndrome. J Surgical Sciences. 4:1–4. 2015.
|
|
54
|
Paduraru DN, Nica A, Carsote M and Valea
A: Adrenalectomy for Cushing's syndrome: Do's and don'ts. J Med
Life. 9:334–341. 2016.PubMed/NCBI
|
|
55
|
Poiana C, Carsote M, Chirita C, Terzea D,
Paun S and Beuran M: Giant adrenal cyst: Case study. J Med Life.
3:308–313. 2010.PubMed/NCBI
|
|
56
|
Caruntu C, Boda D, Constantin C, Caruntu A
and Neagu M: Catecholamines increase in vitro proliferation of
murine B16F10 melanoma cells. Acta Endocrinol. 10:545–558.
2014.
|
|
57
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non melanoma
skin cancer. Oncol Rep. 38:1327–1340. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Grange JD, Duquesne N, Roubeyrol F,
Branisteanu D, Sandon K, Fleury J, Gerard JP, Chauvel P, Pinzaru G,
Jean-Louis B and Bievelez B: Double irradiation for macroscopic
radioresistance or recurrence of melanomas of the posterior uvea:
Clinical, ballistic, thera-peutic and prognostic aspects. Series of
19 cases among 462 patients. J Fr Ophtalmol. 22:1054–1063.
1999.PubMed/NCBI(In French).
|
|
59
|
Ancuceanu R, Dinu M, Neaga I, Laszlo FG
and Boda D: Development of QSAR machine learning-based models to
forecast the effect of substances on malignant melanoma cells.
Oncol Lett. 17:4188–4196. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Stefan O, Tudor G, Constantinescu C, Luca
C, Boda D, Caruntu C, Cioplea M, Nichita L and Zurac SA: E-cadherin
and N-cadherin expression pattern in common melanocytic nevi.
Virchows Archiv. 475 (Suppl):S28. 2019.
|
|
61
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar
|
